Breaking News
Get 40% Off 0
👀 Reveal Warren Buffett's stock picks that are beating the S&P 500 by +174.3% Get 40% Off

Johnson & Johnson: Q2 Earnings Raise Some Questions

By Vince MartinStock MarketsJul 20, 2022 12:03PM ET
www.investing.com/analysis/johnson--johnson-q2-earnings-raise-some-questions-200627386
Johnson & Johnson: Q2 Earnings Raise Some Questions
By Vince Martin   |  Jul 20, 2022 12:03PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
 
US500
-0.12%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
DJI
-0.25%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
MRK
-2.32%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
MDT
+1.76%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
IBM
+2.57%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
JNJ
-1.40%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
  • Latest Johnson & Johnson earnings offer reason for short-term concern
  • Outlook for coming year was reduced
  • Long-term outlook for JNJ, however, should be fine

Second quarter earnings from Johnson & Johnson (NYSE:JNJ) don’t look great. The results did beat Wall Street estimates, certainly. But the outlook for the year was reduced, and the stronger U.S. dollar is a threat to 2023 performance as well.

Indeed, on a green day for the market — the S&P 500 gained 2.76% — JNJ dropped 1.5%. It was one of only two stocks in the Dow Jones Industrial Average to decline during the session; the other, not coincidentally, was IBM (NYSE:IBM), whose own Q2 report looked disappointing as well.

Long-term, JNJ stock should be fine. I argued for the stock back in April; with the price about 6% cheaper, the “buy and hold” case still holds.

Short- to mid-term, however, the Q2 report does highlight some potential reason for worry. Investors still should be looking closely at JNJ, but it seems likely they don’t need to rush in.

The Dollar Problem

With the Federal Reserve raising rates, the U.S. dollar has strengthened markedly. The U.S. dollar index, often referred to as the DXY, has hit a nearly 20-year high:

DXY Chart
DXY Chart

For a multinational, U.S.-based company, the strong dollar can cause some problems. J&J certainly qualifies. In 2021, just shy of half of revenue came from overseas.

A stronger dollar means sales made in other currencies translate at a lower level. For the Consumer Health business — which J&J plans to spin off — competitive problems can also follow, as in-country rivals don’t have the same currency pressures.

The impact of currency was notable in J&J’s Q2 report. Despite the fact that the quarter beat analyst estimates, J&J pulled down its guidance for the year. Adjusted earnings per share now is projected to come in at $10.00-$10.10, against a range of $10.15-$10.35 after Q1.

The reduction came almost entirely from currency impacts: adjusted “operational” EPS was barely changed (the high end of the range came down a nickel).

To be sure, the stronger dollar isn’t destroying J&J results. The midpoint of adjusted EPS guidance was reduced just 2%. But the quarter does raise some concern about that consumer health spin-off. The business didn’t have a great quarter, in part because it’s the most impacted by currency. 55% of 2021 revenue came from overseas, and consumer sales face more competitive pressure than, say, a cancer medication or a knee implant.

Again, this doesn’t break the case for JNJ stock. But it’s possible to see a poor reception for the spin-off next year, given modest top-line growth (U.S. sales actually declined in the quarter) and currency effects. That might dim some optimism for owning JNJ ahead of the spin.

The Market Problem

With the post-earnings decline, JNJ now has declined 8% from its 52-week high. That’s actually quite a strong performance in the context of the broad market: the S&P 500 is down 18% from its peak.

The question is if that outperformance will hold if the market takes another leg down. We’ve seen precisely this pattern before:

J&J Chart
J&J Chart

When broad markets (the blue line here is the S&P 500) turned south in the spring of 2008, JNJ held up. But when the decline in U.S. equities accelerated, J&J stock eventually gave way.

If the recent bounce in the S&P — which has rallied 8.3% from its lows — reverses, JNJ stock probably follows. At about 17x this year’s earnings, the stock appears cheap. But in the context of pharmaceutical and medical device names, 17x earnings implies a reasonable premium. Drug-maker Merck (NYSE:MRK) trades at about 13x 2022 EPS estimates, and medical device giant Medtronic (NYSE:MDT) is at 16x.

Relatively speaking, JNJ is one of the safer stocks out there. But the lesson of 2008-09 is that “relatively” is the key word. A stock that declines at a slower rate than the market still declines.

The Long-Term Case for JNJ Stock

To be sure, this may all be a bit too complicated. Again, I was a bull on the stock near the highs — and long-term, I remain bullish. As I noted earlier this year, J&J commands nearly 1% of worldwide medical spending. That’s an incredible feat, and a reasonable tailwind; as humans get older and developed economies grow, medical spending is going to rise over time.

History too suggests JNJ will be just fine. Including dividends, JNJ has returned 7% over the past year, 8% annualized over the past five, and a total of 230% over the past decade. $10,000 invested 25 years ago would be worth $105,000 now — total returns of almost exactly 10% a year.

Getting that level of return going forward might be a bit more difficult, given political pressures on drug pricing in developed markets and a slower rate of growth in developing economies. But this is still a company that will grow earnings, increase its dividend (J&J has raised its payout for 60 consecutive years), and likely see its stock price rise.

In that context, there’s a “set it and forget it” case for JNJ stock still. But, at the same time, it’s fair to wonder if the stock might be available just a little bit cheaper at some point in the not-too-distant future.

As of this writing, Vince Martin has no positions in any securities mentioned.

Johnson & Johnson: Q2 Earnings Raise Some Questions
 

Related Articles

Johnson & Johnson: Q2 Earnings Raise Some Questions

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Comments (4)
mikailu Muhammad
mikailu Jul 23, 2022 6:03AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
I know all well, but I lost my money in my bank empty. How can you help me? please
Joseph Obrzut
jzut Jul 20, 2022 5:52PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
i had 30 shares at 99.6 06/15. Sold 1 @172. 1 @ 169.6. Now 28.I'll trim probably 3 more if it gets up to the higher part of the chart. BUT this stock will not leave my portfolio.
Art Carrano
Art Carrano Jul 20, 2022 1:23PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Rate hike will be 50bps.
Elison Rios
Elison Rios Jul 20, 2022 1:23PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
nah I believe will be 100bps
Uzochukwu Anyalor
Uzochukwu Anyalor Jul 20, 2022 1:23PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
if not 100bps, then 75bps at least
Kris Jay
Kris Jay Jul 20, 2022 1:23PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
for sure at least 75bps.  Powell isnt quite the man Volcker is so very speculative that he would go 100bps but in fact that is what is needed to kill demand and bring down inflation.
Igor Cendo
Igor Cendo Jul 20, 2022 12:19PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email